August 6, 2007

FDA Approves Selzentry, First in Its Class

The U.S. Food and Drug Administration has approved Pfizer’s HIV entry inhibitor Selzentry (maraviroc), which is expected to be available by mid-September. The drug, which attacks CCR5 receptors on CD4 cells, is the premiere member of the first new class of oral HIV medications in over a decade.